Sign in

    Harry Zhao • Deutsche Bank

    Harry Zhao is currently an analyst at Deutsche Bank, specializing in equity research with a focus on technology and consumer sectors. He covers prominent companies in these areas and has established a strong performance record, consistently delivering insightful investment recommendations and contributing to sector reports. Zhao began his career in finance several years ago, accumulating experience at leading institutions before joining Deutsche Bank, where he quickly distinguished himself through his in-depth analysis and market expertise. He holds professional securities licenses and maintains active FINRA registration, reinforcing his credentials within the investment community.

    Harry Zhao's questions to So-Young International Inc (SY) leadership

    Harry Zhao's questions to So-Young International Inc (SY) leadership • Q4 2024

    Question

    Harry Zhao from Deutsche Bank requested more insight into So-Young's future financial outlook beyond the provided Q1 2025 revenue guidance.

    Answer

    CFO Nick Zhao acknowledged that near-term profitability may be affected by investments in expanding the new aesthetic centers. However, he emphasized that this is a critical part of the long-term vertical integration strategy, which creates a diversified model for financial stability. Mr. Zhao assured that the company maintains a healthy cash flow and a disciplined capital allocation approach, focusing on balancing growth with profitability to drive long-term shareholder value.

    Ask Fintool Equity Research AI

    Harry Zhao's questions to So-Young International Inc (SY) leadership • Q3 2024

    Question

    Harry Zhao from Deutsche Bank asked about the competitive advantages So-Young possesses in its upstream business segment compared to traditional upstream medical aesthetic companies.

    Answer

    CEO Xing Jin, via an interpreter, highlighted So-Young's unique ecosystem-based operational advantage. He cited the rapid growth of their injectable product 'Elasti' and the successful launch of the 'Truelift' ultrasound device as evidence. The company leverages its platform and self-operated clinics to provide targeted marketing and promotional support, turning partner products into bestsellers. This integrated approach, from manufacturing to end-consumer, gives them a distinct edge over traditional players.

    Ask Fintool Equity Research AI